Latham & Watkins and Linklaters have taken lead roles on Watson Pharmaceuticals’ €4.25bn (£3.47bn) acquisition of Actavis in a deal which will create the third-largest global generic drug maker.
US firm Latham advised the acquirer on the deal, which was executed under English law. The firm fielded teams in California and London, with corporate partner Scott Shean heading the US team and Mike Bond the London team. London tax partner Sean Finn also advised, with New York partners Bradd Williamson and Daniel Seale acting on employee benefits and finance matters respectively.
